GlassScriptPhysician profile
Joseph S Galati
NPI 1821069162
$211,207.02
in general payments reported to CMS, 2019-2025
37 companies · $40K in 2025
The $40K reported for 2025 was more than what 83% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,708 · 2020: $15K · 2021: $7,260 · 2022: $50K · 2023: $53K · 2024: $40K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Travel and Lodging: $12K · Consulting Fee: $11K · Food and Beverage: $7,994 · Grant: $3,125 · Education: $37.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $57,977.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,634.00 |
| Travel and Lodging | $11,875.16 |
| Consulting Fee | $10,513.00 |
| Food and Beverage | $7,994.40 |
| Grant | $3,125.00 |
| Education | $37.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61,176.46 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $61,014.64 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $50,888.65 | 2019-2025 | Epclusa |
| Madrigal Pharmaceuticals | $24,546.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Bausch Health US, LLC | $9,104.58 | 2025 | |
| Abbvie INC. | $1,486.19 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $424.36 | 2023-2025 | Iqirvo, Bylvay |
| Echosens North America, INC. | $385.87 | 2025 | Fibroscan |
| Intra-Sana Laboratories | $369.06 | 2021-2022 | |
| Novo Nordisk INC | $280.11 | 2019-2025 | Wegovy |
| Perspectum Diagnostics LTD | $233.29 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $209.80 | 2021-2025 | Utaswako Afp-L3 |
| Shionogi INC | $193.06 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.14 | 2021-2024 | Entyvio |
| Ferring Pharmaceuticals INC. | $129.47 | 2019-2023 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $121.66 | 2022-2023 | Terlivaz |
| Orphalan INC | $114.82 | 2024 | Cuvrior |
| Albireo Pharma, INC. | $102.56 | 2022 | |
| Ardelyx, INC. | $36.87 | 2023 | Ibsrela |
| Olympus America INC. | $36.22 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $34.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.30 | 2024 | |
| Teleflex LLC | $23.10 | 2022 | |
| Merck Sharp & Dohme LLC | $20.09 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $18.69 | 2023 | Prehevbrio |
| Exact Sciences Corporation | $18.69 | 2023 | |
| Vifor Pharma, INC. | $18.35 | 2021 | |
| Celltrion USA INC. | $15.64 | 2025 | Vegzelma |
| Eisai INC. | $13.76 | 2020 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Galati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.